Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab vs Teriparatide in Postmenopausal Osteoporosis (STRUCTURE)
NCT01796301Phase 3Completed
- Sponsor
- Amgen
- Start
- Jan 2013
- Primary completion
- May 2015
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of romosozumab in postmenopausal osteoporosis, sponsored by Amgen. Started Jan 2013; status: completed.
02
Drugs
romosozumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT01796301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01796301.